Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications
Author Information
Author(s): Borella Fulvio, Fucina Stefano, Seminara Ylenia, Denti Pietro, Ferraioli Domenico, Bertero Luca, Gallio Niccolò, Cusato Jessica, Valabrega Giorgio, Revelli Alberto, Marozio Luca, Cosma Stefano
Primary Institution: University of Turin
Hypothesis
The enzyme topoisomerase II alpha (TOP2A) plays a critical role in DNA replication and cell proliferation, making it a promising target for cancer therapy.
Conclusion
Targeting TOP2A could improve treatment outcomes for patients with ovarian cancer, particularly in those with high-grade serous histotypes.
Supporting Evidence
- TOP2A overexpression is associated with poor prognosis in ovarian cancer.
- Studies show that targeting TOP2A can enhance the effectiveness of chemotherapy.
- High levels of TOP2A expression correlate with tumor recurrence and aggressive disease.
- TOP2A inhibitors may improve progression-free survival in patients with ovarian cancer.
Takeaway
TOP2A is an important protein in ovarian cancer that helps cancer cells grow. By targeting it with specific drugs, we might be able to make treatments work better.
Methodology
This review synthesizes findings from multiple studies on TOP2A's role in ovarian cancer and its potential as a therapeutic target.
Potential Biases
Potential publication bias due to the predominance of studies on high-grade serous ovarian cancer.
Limitations
The review primarily focuses on high-grade serous ovarian cancer, which may limit the generalizability of the findings to other histotypes.
Participant Demographics
The studies reviewed included a majority of high-grade serous ovarian cancer patients, with some data on other histotypes.
Statistical Information
P-Value
p ≤ 0.001
Confidence Interval
95% CI: 0.73–1.18
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website